Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery

被引:25
|
作者
Mahmoudian, Mohammad [1 ,2 ,3 ]
Salatin, Sara [1 ,2 ,3 ]
Khosroushahi, Ahmad Yari [4 ,5 ]
机构
[1] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Dept Pharmaceut Nanotechnol, Fac Pharm, Tabriz, Iran
[4] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[5] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Nanotechnol, Daneshgah St,POB 51548-53431, Tabriz, Iran
关键词
Lipoprotein; LDL; HDL; Nanoparticle; Anticancer; Drug delivery; APOLIPOPROTEIN-A-I; RECEPTOR CLASS-B; CANCER CELL-PROLIFERATION; PARENCHYMAL LIVER-CELLS; SCAVENGER RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR; BREAST-CANCER; SR-BI; TARGETED DELIVERY; POTENTIAL CARRIER;
D O I
10.1007/s00280-018-3626-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lipoproteins (LPs) are a set of naturally occurring bio-nanoparticles consisting of Apo-LPs, phospholipids, a highly hydrophobic core of cholesteryl esters and triglycerides that participate mainly in the targeted transport of cholesteryl esters and other hydrophobic molecules through the bloodstream. They also are able to recognize specific receptors on normal and abnormal cells. Therefore, LPs represent a relevant tool for targeted delivery of cancer diagnostics and therapeutics due to their native biocompatibility, biodegradability, nano-scale size and receptor-mediated uptake. The circulating LPs are categorized into five classes, each with its own characteristic protein and lipid composition. Low-density LPs (LDL) and high-density LPs (HDL) are two major subclasses of LPs which were extensively subjected to attractive and versatile vehicles for targeted delivery of anticancer drugs. This study focus to highlight the potential applications of LDL and HDL bio-nanocarriers in the field of specific target drug delivery to cancer cells.
引用
收藏
页码:371 / 382
页数:12
相关论文
共 50 条
  • [21] Treatment options for low high-density lipoproteins
    Hafiane, Anouar
    Kellett, Samantha
    Genest, Jacques
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (02) : 134 - 139
  • [22] ANTIOXIDANT EFFECT OF HIGH-DENSITY LIPOPROTEINS IN PEROXIDATION OF LOW-DENSITY LIPOPROTEINS
    KLIMOV, AN
    KOZHEMYAKIN, LA
    PLESKOV, VM
    ANDREEVA, LI
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1987, 103 (05) : 622 - 625
  • [23] INTERACTIONS OF HIGH-DENSITY LIPOPROTEINS WITH VERY LOW AND LOW-DENSITY LIPOPROTEINS DURING LIPOLYSIS
    MUSLINER, TA
    MICHENFELDER, HJ
    KRAUSS, RM
    JOURNAL OF LIPID RESEARCH, 1988, 29 (03) : 349 - 361
  • [24] The impact of low- and high-density lipoproteins on inwardly-rectifying K plus channels in macrophages
    Gursahani, Kunal
    Singh, Dev
    Epshtein, Yulia
    Chopra, Arun
    Levitan, Irena
    FASEB JOURNAL, 2008, 22
  • [25] ON THERMAL DEPENDENCE OF CONFORMATION OF HUMAN SERUM LOW- AND HIGH-DENSITY LIPOPROTEINS (LDL AND HDL) AND THEIR APOPROTEINS
    SCANU, A
    HIRZ, R
    POLLARD, H
    BIOPHYSICAL JOURNAL, 1969, 9 : A148 - &
  • [26] ROLE OF LOW-DENSITY AND HIGH-DENSITY LIPOPROTEINS IN ATHEROGENESIS
    ASSMANN, G
    SCHRIEWER, H
    NUTRITION AND METABOLISM, 1980, 24 : 19 - 25
  • [27] EFFECT OF HIGH-DENSITY LIPOPROTEINS ON PERMEABILITY OF RABBIT AORTA FOR LOW-DENSITY LIPOPROTEINS
    KLIMOV, AN
    POPOV, AV
    NAGORNEV, VA
    PLESKOV, VM
    VOPROSY MEDITSINSKOI KHIMII, 1984, 30 (06): : 9 - &
  • [28] EFFECT OF HIGH-DENSITY LIPOPROTEINS ON PERMEABILITY OF RABBIT AORTA TO LOW-DENSITY LIPOPROTEINS
    KLIMOV, AN
    POPOV, AV
    NAGORNEV, VA
    PLESKOV, VM
    ATHEROSCLEROSIS, 1985, 55 (02) : 217 - 223
  • [29] Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin
    Yuan, Yue
    Wen, Jian
    Tang, Jie
    Kan, Qiming
    Ackermann, Rose
    Olsen, Karl
    Schwendeman, Anna
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2016, 11 : 6229 - 6238
  • [30] High-density lipoproteins for the systemic delivery of short interfering RNA
    McMahon, Kaylin Marie
    Thaxton, Colby Shad
    EXPERT OPINION ON DRUG DELIVERY, 2014, 11 (02) : 231 - 247